Faisal Khurshid, an analyst from Leerink Partners, reiterated the Buy rating on aTyr Pharma (ATYR – Research Report). The associated price target remains the same with $16.00.
Faisal Khurshid’s rating is based on several anticipated catalysts that could significantly impact aTyr Pharma’s stock performance. He has a positive outlook on the upcoming Phase 3 EFZO-FIT results for efzofitimod in treating pulmonary sarcoidosis, expected in the third quarter. While the updates leading to this readout may not drastically alter the fundamental assessment of the drug’s success probability, they are likely to influence investor perception and risk appetite.
Key catalysts include the presentation of EFZO-FIT baseline characteristics at the American Thoracic Society meeting, a publication on the scientific basis of efzofitimod, initial data from the Phase 2 EFZO-CONNECT study, and potential publication of competitor data. Among these, the ATS presentation is seen as the most impactful for evaluating EFZO-FIT’s potential. These developments are expected to present a significant risk-reward opportunity for investors, supporting Khurshid’s Buy rating.
Khurshid covers the Healthcare sector, focusing on stocks such as Geron, Pliant Therapeutics, and Ironwood Pharma. According to TipRanks, Khurshid has an average return of 36.6% and a 51.85% success rate on recommended stocks.
In another report released on February 13, RBC Capital also maintained a Buy rating on the stock with a $16.00 price target.